SARS-CoV-2 immune response in asymptomatic patients

SARS-CoV-2 immune response in asymptomatic patients - SCOUT-2 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50161

Enrollment

Registered

2020-06-25

Start date

2020-06-25

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 SARS-CoV-2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult (age * 18 years) - Screened for COVID-19 according to the national guidelines because of a planned surgical or interventional procedure under general anesthesia. - Tested positive for SARS-CoV-2 with RT-PCR. - Asymptomatic at the moment of screening: no suspicion for COVID-19 for at least 48 hours prior to screening, based on a standardized questionnaire containing the following complaints: cough, dyspnoea, fever, general malaise, myalgia, headache, extreme fatigue (new onset), throat ache, obstructed/runny nose, loss of smell, loss of taste, abdominal pain, diarrhoea and vomiting.

Exclusion criteria

Exclusion criteria: Not able or willing to give informed consent

Design outcomes

Primary

Measure	Time frame
Levels of serum antibody response to SARS-CoV-2 and phenotypic and functional characterisation of SARS-CoV-2-specific T cells.	—

Secondary

Measure	Time frame
- Neutralisation potency, reactivity against different SARS-CoV-2 and other coronavirus proteins and the effector functions of these antibodies (antibody-dependent cellular cytotoxicity and phagocytosis and complement activation). - IgA antibody levels in saliva. - Comparison of antibody and B/T-cell response to SARS-CoV-2 in post-symptomatic patients (patients who had symptoms in the two weeks before positive screening), truly asymptomatic patients, pre-symptomatic patients (patients who developed symptoms in the two weeks after positive screening), versus those of mild and severe symptomatic patients (METC study 2020_154 and RECoVERED study, ZonMw funded). - Effect of age, comorbidity and RT-PCR cycling threshold values (of the screening PCR). - Development of SARS-COV-2 antibody levels and B/T-cell responses over time (up to one year after positive testing).	—

Measure

Time frame

- Neutralisation potency, reactivity against different SARS-CoV-2 and other coronavirus proteins and the effector functions of these antibodies (antibody-dependent cellular cytotoxicity and phagocytosis and complement activation). - IgA antibody levels in saliva. - Comparison of antibody and B/T-cell response to SARS-CoV-2 in post-symptomatic patients (patients who had symptoms in the two weeks before positive screening), truly asymptomatic patients, pre-symptomatic patients (patients who developed symptoms in the two weeks after positive screening), versus those of mild and severe symptomatic patients (METC study 2020_154 and RECoVERED study, ZonMw funded). - Effect of age, comorbidity and RT-PCR cycling threshold values (of the screening PCR). - Development of SARS-COV-2 antibody levels and B/T-cell responses over time (up to one year after positive testing).

—

Countries

Netherlands

Outcome results